Related Experiment Video

Updated: Aug 30, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Update on giant cell arteritis

Grant W Su1, Rod Foroozan

  • 1Cullen Eye Institute, Baylor College of Medicine, Houston, Texas 77030, USA.

Current Opinion in Ophthalmology
|November 15, 2003
PubMed

Insights

Giant cell arteritis (GCA) is a common vasculitis causing vision loss in older adults. Current treatments, primarily corticosteroids, offer limited visual recovery, necessitating improved diagnostic and management strategies for GCA patients.

Area of Science:

  • Rheumatology
  • Ophthalmology
  • Internal Medicine

Background:

  • Giant cell arteritis (GCA) is the most prevalent systemic vasculitis.
  • It disproportionately affects the elderly population.
  • GCA is a leading cause of preventable visual loss in older adults.

Purpose of the Study:

  • To review current diagnostic approaches for GCA.
  • To discuss contemporary treatment strategies for GCA.
  • To evaluate the visual prognosis in patients diagnosed with GCA.

Main Methods:

  • Literature review of recent evidence on GCA diagnosis and management.
  • Analysis of treatment outcomes and visual prognosis.
  • Development of a clinical algorithm for GCA evaluation.

Main Results:

  • Visual function recovery in GCA patients with existing visual loss is generally poor.
  • Corticosteroids remain the cornerstone of GCA treatment.
  • An evaluation and management algorithm for suspected GCA has been developed.

Conclusions:

  • Despite advancements, corticosteroids are the standard therapy for GCA.
  • Early diagnosis and prompt treatment are crucial for managing GCA.
  • The visual prognosis for GCA patients with visual impairment remains guarded.
Abstract

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...